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The objective of the present study was to alter the crystal habit of itraconazole (ITZ) by
cooling and anti-solvent crystallization and characterize its properties. ITZ was recrystal-
lized in different solvents and the effects of each solvent on morphology of crystals,
dissolution behavior and solid state of recrystallized drug particles were investigated. The
results revealed that ITZ crystals recrystallized by cooling and anti-solvent crystallization
showed the different crystal habits from the untreated ITZ. Using cooling crystallization
tended to provide needle-shaped crystals while the crystals obtained from anti-solvent
crystallization showed more flaky, plate shape. This indicated the importance of prepa-
ration method on nucleation and crystal growth. No change in drug polymorphism was
observed, according to determination of thermal property and crystalline state by differ-
ential scanning calorimetry and powder X-ray diffractometry, respectively. The recrystal-
lized ITZ showed higher drug dissolution than untreated ITZ and the highest drug
dissolution was observed from the samples recrystallized in the presence of PEG 200, which
provided the small plate-shaped crystals with tremendously increased in surface area.
However, the increasing of drug dissolution is relatively small, therefore, further devel-
opment may be required.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).aceutical Technology, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000,
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Crystallization is concerned with the evolution from solution
or melt of crystalline state [1]. The formation of crystals con-
sists of nucleation and crystal growth. Nucleation is the mo-
lecular assembly process, in which the molecules of the
particular element start combining together. Nucleation oc-
curs via the formation of small embryos of the new phase
inside the large volume of the metastable old phase. Nucle-
ation can occur with or without foreign substance, so called
homogeneous and heterogeneous, respectively [2]. Once the
nucleation has been achieved, crystal growth is the domi-
nated process, leading to evaluation of the embryonic crystals
into a crystal form of defined size and shape. The factors
influencing the crystal size and shape are the crystal lattice of
themolecular solids and solvent and additive presented in the
system. The solvents used in crystallization strongly affect the
habit of crystalline material. However, the role played by
solvent interactions in enhancing or inhibiting crystal growth
is still not completely understood [3]. The mechanism of sol-
vent affecting crystal growth and morphology is explained by
Bennema and coworkers [4]. They proposed that favorable
interactions between solute and solvent on specific faces
leads to reduced interfacial tension, causing a transition from
the smooth to a rough interface and a concomitant faster
surface growth. In contrast, preferential adsorption at specific
faces can inhibit their growth as removal of bound solvent
acts as additional energy barrier for continued growth.
The difference in crystal faces affects the nature of each
crystal habit which influences the dissolution of a drug [5].
Adhiyaman and Basu [6] reported that the dissolution
enhancement of dipyridamole correlates to alteration of the
drug habit by crystallization using different solvents, addi-
tives and crystallization conditions. The dissolution rate of
rod-shaped particles crystallized from benzene is notably
more rapid than that of rectangular needle-shaped crystals
produced using methanol. The effect of crystal habit on
tolbutamide dissolution was also suggested [7]. The smallest
particle size, plate-like shape crystals adopted from solvent-
change method using methanol and ethanol show higher
dissolution rate.
Many crystallization methods have been used in pharma-
ceutical sciences, e.g., melt crystallization, cooling crystalli-
zation, anti-solvent crystallization, gas anti-solvent
crystallization and evaporative crystallization. Cooling and
anti-solvent crystallization were the most common crystalli-
zation method used in pharmaceutical application. In cooling
crystallization, the supersaturation is generated by a decrease
in temperature. Cooling crystallization occurswhen a solution
containing solute is cooled at a constant concentration of
dissolved crystals [8]. A similar process occurs for anti-solvent
crystallization, instead of cooling the system, a secondary
solvent known as anti-solvent is added to the original solvent,
resulting in the reduction of the solubility of the solute in the
original solvent and consequently generating a supersatura-
tion driving force [9]. Many studies reported the effect of
various operating conditions. The different concentrations of
aqueous and anti-solvent solutions affect crystal shape and
distribution [10]. The rate of supersaturation generation inanti-solvent crystallization is highly dependent on the anti-
solvent addition rate. Both supersaturation and solvent
composition are also important factors affecting crystal size
and habit.
Itraconazole (ITZ), a poorly water-soluble drug, is a triazole
antifungal agent having a broad spectrum of activity against a
variety of pathogens, including Aspergillus species, Candida
albicans, Cryptococcus neoformans, Coccidioides immitis, Histo-
plasma capsulatum, Paracoccidioides brasiliensis, and Sporothrix
schenckii [11], which are the major cause of opportunistic
infection in human immunodeficiency virus (HIV) infected
patients. Themechanism of action of ITZ is similar to all other
azole antifungals. It inhibits cytochrome P450 of the fungi and
thus interferes the synthesis of ergosterol, a vital component
of the fungal cell membrane, leading to cell death [12]. ITZ is a
white to slightly yellowish powder. It has a molecular formula
C35H38Cl2N8O4 and molecular weight of 705.64. It is a weak
basic drug (pKa¼ 3.7) which is virtually ionized at only low pH,
possessing extremely low water solubility (about 1 ng/ml at
neutral pH and about 6 mg/ml at pH 1).
The objective of this studywas to prepare the recrystallized
ITZ by cooling and anti-solvent crystallization methods. The
properties of recrystallized ITZ, i.e, morphology, surface area,
thermal property, crystalline state and dissolution, were
investigated.2. Materials and methods
2.1. Materials
ITZ raw material used in this study was purchased from
Nosch Labs Private (India). Chloroform (lot number K40141945
924, Merck, Germany) and methylene chloride (lot number
D3056-1-2501 94556-1112, QReC, New Zealand) were used as
crystallizing solvents in halide group while methanol (lot
number I520407 004, Merck, Germany), ethanol (lot number
R:11S:1-16, Liquor Distillery Organization, Thailand), and iso-
propanol (lot number K40861440 010, Merck, Germany) were
used as crystallizing solvents in alcohol group. Polyethylene
glycol (PEG) 200 (lot number 1294947 51807087) and PEG 400
(lot number 1366280 34407P06) were from Fluka (Germany).
Distilledwater was used as an anti-solvent in recrystallization
of ITZ from alcohols and PEGs while hexane (lot number 09 08
1092, Labscan, Thailand) was used as an anti-solvent for
halide solvents. Other chemicals were of reagent or analytical
grade and used without further purification. The simulated
gastric fluid USP without pepsin (SGF) was prepared by dis-
solving 2 g of sodium chloride and 7 ml of hydrochloric acid
into distilled water and adjusting volume to 1000ml, pH to 1.2,
and used as dissolution medium.
2.2. Solubility studies
Solubility of ITZwas determined inwater and various solvents
by adding ITZ in 1 ml of a pure solvent in Pyrex culture tubes.
The drug suspension was equilibrated at 25 C in a thermo-
statically controlled bath for 48 h. After equilibration, the
tubes were centrifuged at 3500 rpm for 15 min and the clear
supernatants were analyzed for ITZ with high performance
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C18 column (5 mm, 4.6  250 mm) (Alltech, Italy). The mobile
phase consisted of 63:37:0.05 acetonitrile:water:diethylamine
adjusting pH to 2.45 with phosphoric acid and was filtered
through a membrane filter (0.22 mm), and degassed in a soni-
cator bath before use. The flow rate was 1.0 ml/min, and the
UV detection wavelength was 263 nm.
2.3. Recrystallization of ITZ
ITZ was recrystallized by twomethods in order to alter crystal
habit or crystalline state of the drug. Three groups of solvents,
that is, alcohols (methanol, ethanol and isopropanol), poly-
ethylene glycols (PEG 200 and PEG 400) and halide solvents
(chloroform and methylene chloride) were used.
2.3.1. Cooling crystallization
ITZ was recrystallized in three groups of solvents as described
above. Supersaturation was achieved by changing the solu-
tion temperature. An appropriate drug amount was dissolved
in a particular solvent volume at 40.0 ± 0.5 C. Solution was
cooled in water bath to 10.0 ± 0.5 C under continuous stirring,
at the cooling rate of about 0.25 C/min. Crystals were recov-
ered by vacuum filtration, washed with distilled water for
three times, dried at room temperature for 24 h, and then kept
in a desiccator.
2.3.2. Crystallization by anti-solvent addition
A solution of ITZ was supersaturated by adding an anti-
solvent to reduce the solubility of the drug in the solution.
The anti-solvent should be miscible with the solvent at any
proportion, and the solute should be relatively insoluble in it.
Thus, for this method, two anti-solvents were selected. Hex-
ane was used as anti-solvent for water-immiscible systems to
generate crystals, whereas distilled water went with water
miscible systems. An appropriate drug amount was dissolved
in a particular solvent volume at 40.0 ± 0.5 C. Crystallization
was started in the warm solution, maintained under contin-
uous stirring, by adding an anti-solvent in a ratio of 2:1 (anti-
solvent:ITZ) solution. After beginning of crystallization, the
liquid was cooled down to 10.0 ± 0.5 C under continuous
stirring. Then, the crystals were vacuum-filtered, washedwith
distilled water for three times, dried at room temperature for
24 h, and kept in the same conditions as mentioned above.
2.4. Morphology examination
ITZ crystals were investigated by a scanning electron micro-
scope (SEM; Maxim-2000, CamScan Analytical, England),
under an accelerating voltage of 15 keV. Crystal samples were
fixed on SEM stubs with double-sided adhesive tape and then
coated in a vacuum with thin gold layer before investigation.
2.5. Surface area measurement
Crystal samples were degassed for at least 3 h at 200 C under
a light vacuum (0.013 Torr) to remove physisorbed material
such as water from the particle surface. Nitrogen gas
adsorption and desorption isotherms were collected using a
surface area analyzer (Nova 2000e, Quantachrome, USA) at77 K. The specific surface area was calculated using Brunnaur,
Emmett and Teller (BET) theory, for three to five adsorption
points in the relative pressure range of 0.05e0.30 using
ultrahigh-purity nitrogen (cross-sectional area 16.2 A˚ 2) as the
adsorbate.
2.6. Differential scanning calorimetry (DSC)
The thermal properties of ITZ after treatment in various
conditions were observed by a Sapphire DSC (Perkin Elmer,
Germany). An accurately weighed amount of sample was
placed inside standard crimped aluminum pan and heated
from 25 to 250 C at a heating rate of 10 C/min under nitrogen
flow (30 ml/min).
2.7. Powder X-ray diffractometry (PXRD)
PXRD analysis was used to investigate the effect of recrystal-
lization condition on the crystalline state of ITZ. PXRD pat-
terns of ITZ crystals were obtained using the X-ray
diffractometer (JDX-3530, JEOL, Japan) at 30 kV, 40mA over the
range of 5e40 2q by the scanning speed of 2/min using Cu Ka
radiation wavelength of 1.5406 A˚.
2.8. In vitro dissolution study
Dissolution studies of ITZ crystalswere performed in triplicate
at 37 ± 0.5 C employing USP apparatus I (basket, 100 mesh)
with a speed of 100 rpm (DT70, Erweka, Germany). The
dissolution vessels were loaded with 1000 ml of dissolution
medium (i.e., SGF, pH 1.2). An accurately weighed amount of
ITZ crystals (0.3 mg) was used to ensure the sink condition in
dissolution medium. Samples were withdrawn from the
dissolution vessels at 5, 10, 20, 30, 60, 90, and 120 min and
passed through 0.45-mm cellulose membrane. Then, the
analysis of ITZ content was done by HPLC assay.
After dissolution test, the sampling medium was immedi-
ately analyzed by HPLC (JASCO PU-2089plus quaternary
gradient inert pump, and a JASCO UV-2070plus multiwave-
length UVevis detector, Jasco, Japan) at a wavelength
of 263 nmusing a Cosmosil 5C18-MS-II (4.6 250mm) column.
The system was operated under isocratic flow at 1 ml/min
using a mobile phase consisting of acetonitrile:water:diethyl-
amine, 63:37:0.05 (by volume), adjusting pH to 2.45 with
phosphoric acid and being filtered through a 0.22-mm mem-
brane filter and degassed in a sonicator bath before use.
Samples collected from dissolution test were injected in the
volume of 100 ml. Data were collected and analyzed by
ChromNav program (Jasco, Japan). The retention time of ITZ
was approximately 5 min.3. Results and discussion
3.1. Solubility of ITZ in various solvents
ITZ has very low solubility in water. This is because of the
predominant nonpolarity of the drug molecules. ITZ cannot
effectively break into the lattice structure of water, hence, the
solubility of the drug in deionized water was only 2.8 mg/ml, as
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in methanol and PEGs. Among alcohols, solubility decreased
with increased chain length while increasing of chain length
of the PEGs increased solubility of the drug. Very high solu-
bility of ITZ has been observed in organic solvents, i.e., 30,720
and 28,400 mg/ml for chloroform (CHCl3) and methylene
chloride (CH2Cl2), respectively.
Polarity of the solvent is an important factor governing the
solubility of the drug. However, it is not the only factor
involved. Among alcohols, solubility did not increase with a
decrease in polarity. At 25 C, dielectric constant of methanol,
ethanol and isopropanol is 33.77, 24.35 and 19.45, respectively
[13,14]. The solubility was maximum in methanol and
decreasedwith an increase in the chain length of alcohol. This
effect indicated that the ability of the solvent to form
hydrogen bonds with hetero-atom in the drug molecule is
another important factor that influenced solubility of the drug
in alcohols [15]. As the alkyl chain length in alcohols
increased, their ability to form hydrogen bonds with the drug
molecules decreased, especially for alcohol with branched
methyl group, hence, the solubility decreased [16]. For the
same reason, in case of PEGs, even though the polarity of PEG
is less than ethanol [17], the solubility of the drug could be
higher because of extensive hydrophobic interactions with
the solvents of long nonpolar part in PEG molecules.
3.2. Crystal morphology
ITZ crystals were columnar in shapewith a wide range of size,
between 5 and 20 mm (Fig. 1a). After recrystallization, the
crystal morphology was changed depending on both types of
solvent and recrystallization methods. Fig. 1bef show the
morphology of ITZ crystals obtained from cooling crystalli-
zation. Supersaturation in cooling crystallization process is a
result fromdecreasing of the solution temperature. During the
cooling process, nucleation occurred and solute molecule
could rest on the crystal surface. After the cooling crystalli-
zation process, there was no crystal observed from the PEG
200 and PEG 400 systems. This may be due to lack of nucle-
ation occurred in PEG in the crystallizing temperature [18].
The influence of crystallization solvent on habit modification
of ITZ crystals was clearly shown. Cooling crystallization
process in methanol (Fig. 1b) and ethanol (Fig. 1c) provided
needle-shaped crystals. The use of isopropanol (Fig. 1d), which
has lower polarity, as crystallizing solvent resulted in various
sizes of blade-shaped crystals. Using methylene chloride and
chloroform as crystallizing solvent provided different crystalTable 1 e Solubility of ITZ in various solvents (n ¼ 3).
Type of solvent Solubility of ITZ (mg/ml)
Deionized water 2.8 ± 0.2
Hexane (C6H14) 440 ± 2
PEG 400 347 ± 3
PEG 200 560 ± 14
Isopropanol (C3H7OH) 96 ± 4
Ethanol (C2H5OH) 380 ± 7
Methanol (CH3OH) 745 ± 35
Methylene chloride (CH2Cl2) 28,400 ± 792
Chloroform (CHCl3) 30,720 ± 226habits. Small plate-shaped crystals were obtained from cool-
ing crystallization inmethylene chloride (Fig. 1e) but the small
blade-shaped crystals were obtained after crystallization in
chloroform (Fig. 1f). Comparing SEM images of crystals ob-
tained from chloroform with those obtained from other sol-
vents, the crystal shape of ITZwas significantly changed to the
plate shape, which is quite different from the previous needle
shape. The variation in face dimension or the appearance or
disappearance of some faces could be the cause of change in
morphology of ITZ crystals using different solvents in
recrystallization [3]. The results also demonstrated the dif-
ference in size of recrystallized crystals compared to the un-
treated ITZ.
The morphology of ITZ crystals obtained from anti-solvent
additionmethod is shown in Fig. 2. For crystallization by anti-
solvent addition in alcohols, higher polarity alcohols tended to
provide more flaky crystals than lower polarity ones. In
methanol, the crystals became plate-like (Fig. 2a) while in
other alcohols, ITZ crystals turned to needle shape with more
flakes (Fig. 2b and c). Anti-solvent crystallization of ITZ in
methylene chloride resulted in long and thin needle-shaped
crystals (Fig. 2d). Using chloroform as crystallizing solvent,
irregular shape and flaky crystals were observed (Fig. 2e),
similar to those in the case of using PEGs (Fig. 2f and g).
The growth of one set of crystal faces can be inhibited or
the other set of faces can be induced to grow faster when
particular solvents are used [3]. In this study, using higher
polarity alcohols tended to provide the plate-shaped crystals
while needle-shaped crystals occurred when using the lower
polarity one. This can be explained by the interaction between
the solvent molecules and different crystal faces, which is
believed to change the crystal morphology [19]. It is suggested
that polar solvents were adsorbed by polar faces and non-
polar solvents by the non-polar faces. Since the interaction
of methanol is stronger than isopropanol, the growth of
crystal from the polar faceswasmore inhibited and the crystal
growth was continued from other sides [20].
3.3. Surface area
Reduction of crystal size or increase in surface area of the drug
is awidely usedmethod to increase dissolution rate, under the
NoyeseWhitney equation. The surface area of ITZ crystals is
shown in Table 2. The untreated ITZ provided the lowest
surface area of 4.17 m2/g while all processed crystals showed
an increase in the surface area. The crystals prepared by anti-
solvent crystallization in PEG 200 demonstrated the highest
surface area of 524.90 m2/g, which is 125-fold higher than the
untreated ITZ. Therefore, the improvement of ITZ dissolution
by anti-solvent recrystallization in PEG 200 is expected. The
crystals obtained from cooling crystallization were not
included in this study due to the very low amount of crystal
samples.
3.4. Thermal properties of ITZ crystals
The polymorphs always have different levels of thermody-
namics stability and an unstable, so called metastable form,
canmelt at a temperature less than themelting point of stable
form [4]. Therefore, the DSC was used as primary screening of
Fig. 1 e SEM images of (a) untreated ITZ crystals, and ITZ crystals obtained from cooling crystallization in (b) methanol, (c)
ethanol, (d) isopropanol, (e) methylene chloride, (f) chloroform. The magnifications are 1000£.
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Fig. 3 shows the DSC thermograms of ITZ crystals recrystal-
lized by cooling crystallization and anti-solvent addition
methods.
The onset melting temperature and enthalpy (DH) of
recrystallized ITZ crystals are given in Table 3. It is observed
that there was a noticeable reduction in the enthalpy of the
obtained crystals in comparison with untreated ITZ. Crystals
obtained from crystallization by anti-solvent addition in
methanol showed the lowest enthalpy of 92.63 J/g alongwith a
lower onset temperature. A decrease in onset melting tem-
perature of the obtained crystals may be due to the decreased
drug crystallinity or residual solvent presented as impurities
in the drug crystals. It is well known that the melting tem-
perature and enthalpy rely on crystal size [21]. In particular,
the decrease in crystal size reflected in the decrease inmelting
temperature/enthalpy. The explanation of these phenomenais based on the different structure of surface and bulk phases.
Atoms at the surface are in a less limited arrangement than in
the bulk; therefore, their energy is higher than that of bulk
atoms. Hence, lattice break-down on crystal surface would
require less energy and would be favored with respect to bulk
lattice break-down [21].
From the results, it is clear that there are alterations of
thermal properties of ITZ crystals recrystallized by various
solvents and conditions. To check the drug polymorphism,
PXRD was used (discussed later). Due to very low yield ob-
tained and very high amount of solvent required in prepara-
tion of drug crystals by cooling crystallization, it may be not
practical to use in pharmaceutical industry. Therefore, the
experiments on this technique were excluded. The further
experiment focused on anti-solvent addition technique which
could alter crystal habit and also yield high amount of
crystals.
Fig. 2 e SEM images of ITZ crystals obtained from anti-solvent addition crystallization in (a) methanol, (b) ethanol, (c)
isopropanol, (d) methylene chloride, (e) chloroform, (f) PEG 200, and (g) PEG 400. The magnifications are 1000£.
Table 2 e Surface area of ITZ crystals.
Method Surface area (m2/g)
Untreated ITZ 4.17
Methanol anti-solvent 12.22
Ethanol anti-solvent 8.60
Chloroform anti-solvent 12.59
Methylene chloride anti-solvent 9.43
PEG 200 anti-solvent 524.90
PEG 400 anti-solvent 24.03
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The PXRD pattern of untreated ITZ crystals is shown in Fig. 4.
There are many peaks associated with crystallinity. However,
the most intense peak was located at the same position of ITZ
reported in the previous study [22] in which the PXRD peaks at
values of 2qwere at 17.45 and 17.95 (doublet), 20.30, and 23.45.
A polymorphic form of ITZ was pointed out in 2007 [23], which
Fig. 3 e DSC thermograms of ITZ crystals recrystallized by
(a) cooling crystallization and (b) anti-solvent addition
method.
Fig. 4 e Powder X-ray diffraction patterns of ITZ crystals
recrystallized by anti-solvent addition; recrystallized from
(a) alcohols and (b) PEGs.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 3 0e2 3 8236was characterized by peaks at values of 2q of approximately
7.3, 19.9, 21.9, 26.1, and 32.2.
Even though DSC thermograms of recrystallized ITZ
showed the shift of the onset melting temperature, indicating
the possible polymorphic formation, the PXRD patterns of
these crystals were not different from that of untreated ITZ.
The PXRD patterns still showed the sharp peaks with straight
base lines referred to crystallinity. However, a decrease in
intensity was observed in case of anti-solvent addition crys-
tallization using alcohols and PEGs as primary solvent, as
shown in Fig. 4. This may be due to the decrease in crystal-
linity of ITZ or the presence of residual solvents. However, theTable 3 e Average melting temperature and enthalpy of ITZ cr
Average melting temperature (C)
Cooling crystallization Anti-solvent ad
ITZ untreated 167.73 ± 0.12
Methylene chloride 167.03 ± 0.09 167.70 ± 0.2
Chloroform 168.03 ± 0.40 166.37 ± 0.2
Methanol 165.53 ± 0.29 166.23 ± 0.6
Ethanol N/A 166.33 ± 0.6
Isopropanol 168.20 ± 0.45 166.97 ± 1.0
PEG 200 N/A 164.20 ± 0.8
PEG 400 N/A 163.20 ± 0.4
N/A ¼ not applicable.residual PEGs were not found according to the PXRD patterns
in the Fig. 4b. The PXRD patterns of ITZ crystals recrystallized
by anti-solvent addition using methylene chloride and chlo-
roform (Fig. 5) as the crystallizing solvent showed high in-
tensity and sharp peaks similar to untreated ITZ, indicating no
change in the polymorphism. It is suggested that, in these
cases, only the change in crystal habit occurred.
3.6. In vitro dissolution study
The dissolution of untreated ITZ was about 6% in 2 h while
most of the prepared crystals showed higher drug dissolution.
Crystals obtained from anti-solvent crystallization using PEG
200, which provided the highest surface area, showed theystals (n ¼ 3).
DH (J/g)
dition Cooling crystallization Anti-solvent addition
125.60 ± 19.11
2 109.70 ± 19.86 108.73 ± 8.10
5 122.33 ± 6.16 119.37 ± 22.67
0 119.33 ± 16.05 92.63 ± 11.56
0 N/A 108.33 ± 6.27
8 128.00 ± 0.65 100.20 ± 4.14
0 N/A 107.00 ± 2.59
5 N/A 110.33 ± 10.68
Fig. 5 e Powder X-ray diffraction patterns of ITZ crystals
recrystallized by anti-solvent addition; recrystallized from
halide solvents.
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Fig. 7 e Relationship between dissolution rate and
enthalpy of the crystals obtained from various conditions.
Deviation is observed for the crystals obtained from anti-
solvent addition using isopropanol (*) and PEG 200 (**).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 3 0e2 3 8 237highest drug dissolution of about 10% (Fig. 6). The amount of
drug dissolution fromanti-solvent addition could be ranked as
PEG 200 > methanol > chloroform > PEG
400 > isopropanol > ethanol > methylene chloride. This may
be due to the reduction of melting temperature and enthalpy
(Table 3) and also the change in surface area (Table 2) and
morphology of the crystals (Figs. 1e2). The amount of drug
dissolution from cooling crystallization using chloroform and
methylene chloride was slightly lower than that of untreated
ITZ and ITZ prepared from anti-solvent addition using the
same solvent. However, the amount of drug dissolution from
anti-solvent addition using methylene chloride was not
significantly different (P > 0.05) from that of untreated drug. It
is likely due to the insignificant difference between the
melting temperature of both untreated ITZ and ITZ prepared
from anti-solvent addition usingmethylene chloride (Table 3).
In order to examine the relationship between enthalpy of
the crystals obtained from various conditions and dissolution
rate, we have plotted the dissolution rate against the enthalpy
and calculated the regression line of this system (Fig. 7). TheFig. 6 e Dissolution profiles of ITZ crystexperimental data gave a straight line (r2 ¼ 0.8035) and its
slope was 0.0024, indicating a good correlation between
enthalpy of the crystals and dissolution rate. The decrease in
enthalpy tended to increase the drug dissolution. These data
suggested that the drug dissolution could be estimated from
the enthalpy data obtained by thermal analysis [24]. However,
deviation is found for crystals with high enthalpy which
showed a high amount of drug dissolution. The non-related
dissolution and enthalpy is demonstrated as (*) and (**) in
Fig. 7, which represented the crystals obtained from anti-
solvent addition using isopropanol and PEG 200 as the crys-
tallizing solvent, respectively. The amount of drug dissolution
from crystals obtained from anti-solvent addition using PEG
200, which is plate-shaped and high enthalpy, was more than
that from anti-solvent addition using isopropanol, which is
needle-shaped and lower enthalpy. Small flaky, plate-like
crystals providing more surface area leaded to higher drug
dissolution, than larger needle- or blade-like crystals. Keraliya
and coworkers [7] also reported the influence of crystalals obtained from recrystallization.
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tals with small plate-like shape showed higher dissolution
rate than the large crystals with needle, cubic, and prismatic
crystal habits.4. Conclusion
Different crystal habits of ITZ were prepared by cooling crys-
tallization and anti-solvent addition techniques using various
crystallizing solvents. There was no polymorphic form of ITZ
observed from PXRD pattern; therefore, the change of crystals
may result from the alteration of crystal habit and enthalpy.
Dissolution rate of the crystals was also influenced by crystal
habit and enthalpy. The dissolution rate of recrystallized ITZ
showed almost linear relationship with the enthalpy, how-
ever, some exceptions were found. Although the enthalpy of
the crystals prepared from anti-solvent addition using PEG 200
was high, they could enhance the drug dissolution by 2 folds,
compared to the untreated ITZ, which was the highest
amount in this study. Thismay be due to their small plate-like
morphology which could provide high surface area. Thus, the
dissolution of the drug could be enhanced more than larger
crystal habit. Recrystallization is a promising technique to
alter physicochemical properties of the poorly water-soluble
drugs. The change of recrystallizing methods and conditions
also alters the properties of drug crystals.
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